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Abstract: We present a case of a female patient who developed acute onset of visual loss due to central serous retinopathy 
as a consequence of steroid premedication for docetaxol given as second line neoadjuvant chemotherapy for breast cancer. 
Central serous retinopathy is a recognised association with steroids but has not been previously reported in association with 
the management of solid tumours. Reduction in steroid dose and duration permitted recovery of her visual acuity while 
allowing completion of the prescribed chemotherapy regimen. An overview of the presentation, pathogenesis, aetiologies 
and management of central serous retinopathy is given.
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Case History
History
A 42 year old female presented with several weeks history of a lump in the left breast. She had a history 
of congenital dislocation of the hip, menorrhagia investigated with normal laparoscopy and had been 
treated for a dry eye syndrome of unknown aetiology. She had previously been treated for anxiety and 
depression. She was not on any medications. She was premenopausal and had 2 children both delivered 
by caesarean section. She had no signiﬁ  cant family history.
Examination
Examination revealed a 6 by 7 cm mass in the upper outer quadrant of the left breast extending to the 
areola. There was associated skin tethering but no ﬁ  xation to deeper structures. There were mobile 
lymph nodes palpable in the medial aspect of the left axilla. The remainder of the examination was 
unremarkable. Her clinical staging was T4bN1M0.
Investigations
Mammography and ultrasound conﬁ  rmed a malignant appearing lesion at least 6 cm in diameter and 
ultrasound guided core biopsy showed invasive lobular carcinoma which was ER positive. Baseline 
liver and renal function tests, calcium and full blood count were normal other than a mild iron deﬁ  ciency 
anaemia, which was thought secondary to menorrhagia. Chest radiograph and liver ultrasound showed 
no evidence of metastatic disease. MRI conﬁ  rmed a 7 cm area of malignant appearing enhancement in 
the left breast, with no abnormality in axilla or contra lateral breast. (Fig. 1a)
Management
In view of the locally advanced nature of her carcinoma she was offered neoadjuvant chemotherapy 
with FEC (5 ﬂ  uorouracil 600 mg/m
2, epirubicin 60 mg/m
2 and cyclophosphamide 600 mg/m
2).38
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Progress
After 3 cycles of chemotherapy there had been 
little improvement in the size of the lump on 
clinical examination. A further MRI (Fig. 1b) 
showed no change in the malignant enhance-
ment within the left breast. A new area of malig-
nant type enhancement was noted within the right 
breast which was impalpable. She proceeded with 
2nd line neoadjuvant chemotherapy using 
docetaxol (100 mg/m
2) which was given with 
dexamethasone cover for 72 hours commencing 
24 hours before each cycle at a dose of 8 mg 
twice daily.
Following the 2nd cycle she was re examined 
and the lesion in the left breast had shrunk to 4 cm 
by 5 cm and was now poorly deﬁ  ned. There was 
no palpable lesion in the right breast. After the 3rd 
cycle she developed acute loss of visual acuity in 
the left eye such that she was only able to count 
ﬁ  ngers, vision in the right eye was unaffected. The 
differential diagnosis included choroidal or retinal 
metastasis, retinal detachment, or other retinal 
pathology. Indirect opthalmoscopy revealed sub 
macular fluid and fluorescein angiography 
(Fig. 2a), (Fig. 2b) and (Fig. 2c) showed the very 
rare but classical “smoking stack” appearance. A 
diagnosis of steroid induced central serous reti-
nopathy was therefore made. After discussion with 
the patient and ophthalmologist the decision was 
made to reduce the duration of steroid premedica-
tion to 24 hours only. On this regime she com-
pleted the course of 6 cycles of docetaxol without 
deterioration in her visual symptoms and without 
further incident. A further MRI was performed 
(Fig. 1c) which showed an excellent response to 
treatment and this was conﬁ  rmed clinically. She 
proceeded to surgery and underwent bilateral 
mastectomy. Histological examination of the left 
breast conﬁ  rmed a 20 mm focus of grade 2 mul-
tifocal, lobular carcinoma, which was oestrogen 
receptor positive and Her2 receptor negative. Four 
out of thirty two nodes contained malignant foci. 
Histological examination of the right breast 
showed no evidence of residual disease.
Postoperatively she received radiotherapy to the 
left chest wall and supraclavicular fossa giving 40Gy 
in 15 fractions over 3 weeks. She was commenced 
on tamoxifen. At her most recent attendance, 3 years 
after her original presentation, she was well with no 
signs of disease recurrence and her visual acuity has 
improved an is now back to baseline.
Figure1a. Baseline dynamic contrast enhanced breast MRI demon-
strating  extensive malignant type enhancement in the left upper 
outer breast.
Figure 1b. Dynamic contrast enhanced Breast MRI following 4 cycles 
FEC demonstrates continuing malignant enhancement in the left 
upper outer breast but a new enhancing lesion in the right upper 
outer breast, these two areas have similar malignant type contrast 
enhancement characteristics.
Figure 1c. Dynamic contrast enhanced Breast MRI following 6 cycles 
Docetaxol shows no residual abnormal enhancement and complete 
resolution of the previous highly suspicious, typically malignant MR 
ﬁ  ndings.39
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Discussion
Central serous retinopathy
Central serous retinopathy is an idiopathic 
condition predominantly affecting the macula 
region of the retina. It is characterised by a 
circumscribed area of sub retinal ﬂ  uid.
The pathogenesis is uncertain and postulated 
mechanisms include dysfunction of the retinal 
pigment epithelium or choroidal vascular abnor-
malities. [Hirami et al. 2007] Sub retinal plaques 
Figure 2a. Left fundal image showing central serous retinopathy-with central pigment epithelial changes with overlying sub retinal ﬂ  uid.
Figure 2b. Early ﬂ  uorescein angiogram showing ﬂ  uorescein leak.40
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thought to be due to deposition of ﬁ  brin have been 
identiﬁ  ed, suggesting increased permeability of the 
capillaries. [Ie et al. 1993] Indocyanine-green 
angiography has conﬁ  rmed dye leakage from sub 
retinal choroidal vessels, which is thought to be 
due to hyperpermeability. [Piccolino and Borgia, 
1994; Piccolino et al. 1995; Kitaya et al. 2003] It 
has also identiﬁ  ed delayed arterial ﬁ  lling followed 
by vessel congestion, which is believed to be 
responsible for the development of hyperpermeable 
choroid. [Prunte and Flamer, 1996; Prunte, 1995]
The aetiology of this condition is unknown, but 
there are numerous reported associations. It more 
commonly affects male patients and can occur at 
any age. [Spaide et al. 1996] Certain personality 
traits, particularly the so-called “type A” personal-
ity have been suggested as a risk factor. [Yannuzzi, 
1987] As in the case presented here, steroids are 
one of the commonly reported associations. It is 
reported in association both with endogenous Cush-
ings [Bouzas, 1993] and with exogenous steroid 
administration. It may occur after systemic, inhaled 
or intraepidural steroids. [Haimovici et al. 1997; 
Iida et al. 2001] The effect is not thought to be dose 
dependent and may occur long after commence-
ment of steroids. [Abu el Asrar, 1997; Koyama et al. 
2004] It has been reported with steroid use during 
the treatment of haematological malignancy, for 
example in the treatment of Non Hodgkin’s 
lymphoma. [Bandello et al. 1995] There are no 
previous reports in association with the treatment 
of solid tumours. Other reported associations 
include, pregnancy [Sunness et al. 1993], sympa-
thomimetic medication [Michael et al. 2003], H 
pylori infection [Cotticelli et al. 2006] and with 
sidenaﬁ  l. [Allibhai et al. 2004]
This condition is usually asymptomatic unless 
the macula is affected in which case patients pres-
ent with blurred vision, distortion or loss of visual 
acuity although this is usually mild. Diagnosis is 
based on the ophthalmoscopic ﬁ  ndings of sub reti-
nal ﬂ  uid, and conﬁ  rmed with ﬂ  uorescein angiogra-
phy. A characteristic “smoke stack” appearance may 
be seen as ﬂ  uorescein leaks into the subretinal space 
over the course of the angiogram. Treatment is 
usually expectant together with the discontinuation 
of exacerbating factors, including steroids, if pos-
sible. In those with persistent problems photody-
namic therapy may be helpful. [Cardillo et al. 2003; 
Taban et al. 2004; Mennel et al. 2007] As in our 
patient, the natural history is one of spontaneous 
resolution, with near full recovery of visual acuity. 
However the condition may recur in up to ﬁ  fty 
percent. [Gilbert et al. 1984] In some cases it may 
develop into a chronic condition resulting in irre-
versible visual impairment. [Loo et al. 2006]
Figure 2c. Late ﬂ  uorescein angiogram showing classic “smoke stack” leakage of ﬂ  uorescein and accumulation in overlying sub retinal ﬂ  uid.41
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The role of steroid premedication 
during docetaxol administration
Docetaxol is a semi synthetic taxane. Paclitaxol, 
its parent compound, was derived from Yew tree 
bark. Initial phase II studies using Taxanes were 
conducted without premedication. [Chevallier 
et al. 1995; Dieras et al. 1994] These studies 
demonstrated high overall response rates but also 
showed high levels of ﬂ  uid retention, which was 
severe enough to require discontinuation of 
treatment in up to 50 percent. Studies comparing 
premedication against various regimens have also 
shown high levels of hypersensitivity reactions and 
rash in those treated without premedication. 
[Eisenhaur et al. 1994] A 5-day steroid regimen 
was shown to reduce the incidence of both hyper-
sensitivity and ﬂ  uid retention. Comparison of a 5 
and 3-day regime showed that both were effective 
in reducing the incidence and severity of ﬂ  uid 
retention when compared to no premedication. 
They also postponed the time to ﬂ  uid retention and 
allowed a higher total dose of Taxane to be 
administered. This effect was more marked in the 
group receiving a 5-day regimen of premedication. 
However the 5-day group also had higher overall 
incidences of infection, stomatitis and diarrhoea. 
The study concluded that the 3-day regime had an 
overall better risk beneﬁ  t ratio than a 5-day regime. 
[Riva and Lebeck, 1996] A further study examined 
the role of a 24-hour premedication regime in 
combination with antihistamine. This concluded 
that while it did reduce the incidence of toxicities 
from the taxane it was less effective in doing so 
than the 3-day regimen. [Fulmoleau et al. 1996] 
The current recommendation is therefore that all 
patients should be premedicated with a 3-day 
regime of steroids, which should be commenced 
24 hours prior to chemotherapy. In the case 
presented here the patient was able to complete 3 
further cycles on a reduced steroid regime to just 
24 hours without further toxicity.
Conclusion
A case is presented, of a woman who developed 
central serous retinopathy, an uncommon complica-
tion of steroid treatment which has not been previ-
ously reported in association with the treatment of 
solid tumours. It illustrates that it should not be 
assumed that high risk cancer patients who develop 
serious symptoms have developed metastatic 
disease. Clinicians should be alert to both the 
possibility of non malignant diagnoses in onco-
logical patients and to the possibility of treatment 
related complications. With the increasing use of 
Taxanes in the management of solid tumours this 
particular treatment related complication may be 
seen more commonly. When such complications 
develop it is often necessary to make difﬁ  cult 
decisions regarding further management on the 
basis of potential risk beneﬁ  t ratios. In this case it 
was clearly vital to continue with docetaxol 
chemotherapy, but with a reduced dose of steroid 
premedication, in order to optimise her chance of 
visual recovery. However this was coupled with the 
risk that she might experience additional toxicities 
as a consequence of the reduction in steroid 
premedication, which was a challenging scenario 
in an understandably very anxious patient.
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